98%
921
2 minutes
20
We investigated the influence of degenerated retinal networks on the efficacy of subretinal prosthetic devices in eliciting retinal neural responses. We present a computational model that incorporates intricate descriptions of retinal connectivity spanning neural layers, conductance-based cellular and synaptic parameters, and analytical formulas governing the electrical field. Our results suggest the possibility of selective modulation of functionally-distinct retinal pathways through subretinal stimulation, even in the absence of all photoreceptors. However, we observed a decreasing level of selectivity as inter-neuron synapse and gap junctions were progressively reduced. In addition, our model predicts a more pronounced influence of the integrity of the inner retinal network on electrically induced OFF compared to ON retinal ganglion cell activity. This phenomenon is ascribed to the unique inner retinal network properties of ON versus OFF pathways and changes in these properties upon photoreceptor loss. By precisely controlling the parametric values defining synaptic and gap junction connectivity in the inner retina, we can simulate the impact of different degrees of retinal degeneration on the retina's response to electrical stimulation. This model can assess the retinal network's response to remodeling events across different retinal degeneration stages, offering insights to guide the future development of retinal prosthetic devices and stimulation strategies. Such advancements hold promise for benefiting patients at various stages of retinal disease progression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/EMBC53108.2024.10782307 | DOI Listing |
Alzheimers Dement
September 2025
Department of Neurology, Beijing TianTan Hospital, Capital Medical University, Beijing, China.
Cognitive impairment and dementia, including Alzheimer's disease (AD), pose a global health crisis, necessitating non-invasive biomarkers for early detection. This review highlights the retina, an accessible extension of the central nervous system (CNS), as a window to cerebral pathology through structural, functional, and molecular alterations. By synthesizing interdisciplinary evidence, we identify retinal biomarkers as promising tools for early diagnosis and risk stratification.
View Article and Find Full Text PDFRetina
August 2025
Department of Vitreoretinal Services, K. B. H. Bachooali Charitable Ophthalmic and ENT Hospital, Mumbai Maharashtra, India- 400012.
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
Retin Cases Brief Rep
September 2025
Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California of Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, California, United States.
Purpose: To describe a case of recalcitrant bilateral peripapillary pachychoroid syndrome (PPS) treated with high-dose (HD) intravitreal aflibercept injections.
Methods: Medical and imaging records were retrospectively evaluated. Multimodal imaging included ultra-widefield indocyanine green and fluorescein angiography and fundus autofluorescence.
Mol Ther Methods Clin Dev
June 2025
Shanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.
View Article and Find Full Text PDF